LYMPHOMA, NON-HODGKIN
Clinical trials for LYMPHOMA, NON-HODGKIN explained in plain language.
Never miss a new study
Get alerted when new LYMPHOMA, NON-HODGKIN trials appear
Sign up with your email to follow new studies for LYMPHOMA, NON-HODGKIN, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Lymphoma drug combo trial for youth halted after just 5 patients
Disease control TerminatedThis early-phase trial tested a combination of two immune-boosting drugs, relatlimab and nivolumab, in children and young adults with Hodgkin or non-Hodgkin lymphoma that had come back or not responded to treatment. The goal was to check safety, drug levels, and whether the tumor…
Matched conditions: LYMPHOMA, NON-HODGKIN
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope for tough blood cancers: early trial of ONO-7018 begins
Disease control TerminatedThis early-stage study tested a new drug called ONO-7018 in 9 adults with non-Hodgkin lymphoma or chronic lymphocytic leukemia that had returned or stopped responding to other treatments. The main goal was to find a safe dose and check for side effects. The study was stopped earl…
Matched conditions: LYMPHOMA, NON-HODGKIN
Phase: PHASE1 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Experimental combo for tough lymphoma shows early promise, but trial halted
Disease control TerminatedThis early-stage trial tested a combination of two oral drugs, tazemetostat and venetoclax, in people with non-Hodgkin lymphoma that had come back or stopped responding to treatment. Only 3 people enrolled before the study was terminated. The main goals were to find the safest do…
Matched conditions: LYMPHOMA, NON-HODGKIN
Phase: PHASE1 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New lymphoma drug trial halted early
Disease control TerminatedThis study tested a new drug, PF-08046045, in 22 adults with advanced lymphomas (cancers of the immune system). The goal was to find a safe dose and check for side effects. The trial was stopped early, so results are limited.
Matched conditions: LYMPHOMA, NON-HODGKIN
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC